Malaseb vet. Hársápa 2 % w/v Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

malaseb vet. hársápa 2 % w/v

dechra veterinary products a/s* - chlorhexidinum díglúkónat; miconazolum nítrat - hársápa - 2 % w/v

Saniotic vet. (Mitex vet.) Eyrnadropar/húðdreifa 5,0 mg/0,5293 mg/23,0 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

saniotic vet. (mitex vet.) eyrnadropar/húðdreifa 5,0 mg/0,5293 mg/23,0 mg/ml

vetviva richter gmbh - miconazolum nítrat; prednisolonum acetat; polymyxinum b súlfat - eyrnadropar/húðdreifa - 5,0 mg/0,5293 mg/23,0 mg/ml

Plenvu Mixtúruduft, lausn Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

plenvu mixtúruduft, lausn

norgine b.v. - macrogol 3350; natrii ascorbas inn; sodium sulfate anhydrous; acidum ascorbicum inn; natrii chloridum; kalii chloridum - mixtúruduft, lausn

Movicol Junior Neutral Mixtúruduft, lausn 6,9 g Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

movicol junior neutral mixtúruduft, lausn 6,9 g

norgine healthcare b.v. - macrogol 3350; sodium hydrogen carbonate; kalii chloridum; sodium chloride - mixtúruduft, lausn - 6,9 g

Movicol Mixtúruduft, lausn 13,8 g Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

movicol mixtúruduft, lausn 13,8 g

norgine healthcare b.v. - macrogol 3350; sodium chloride; sodium hydrogen carbonate; kalii chloridum - mixtúruduft, lausn - 13,8 g

Moviprep Mixtúruduft, lausn Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

moviprep mixtúruduft, lausn

norgine b.v. - macrogol 3350; natrii sulfas; natrii chloridum; kalii chloridum; acidum ascorbicum inn; natrii ascorbas inn - mixtúruduft, lausn

Pevisone Krem 1 % Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

pevisone krem 1 %

karo pharma ab* - econazolum nítrat; triamcinolonum acetóníð - krem - 1 %

Xenleta Evrópusambandið - íslenska - EMA (European Medicines Agency)

xenleta

nabriva therapeutics ireland dac - lefamulin acetate - pneumonia, bacterial; community-acquired infections - sýklalyf fyrir almenn nota, - xenleta is indicated for the treatment of community-acquired pneumonia (cap) in adults when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of cap or when these have failed. Íhuga ætti að opinbera leiðsögn á réttri notkun af sýklalyfjum.